Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
ImmaticsN. V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.
The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage.
The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages.
The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications.
ImmaticsN. V. is headquartered in Tübingen, Germany.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 14, 24 | -0.03 Increased by +88.46% | -0.21 Increased by +85.71% |
| Mar 21, 24 | -0.30 Decreased by -30.43% | -0.32 Increased by +6.25% |
| Nov 14, 23 | -0.32 Increased by 0.00% | -0.36 Increased by +11.11% |
| Aug 17, 23 | -0.32 Decreased by -45.45% | -0.25 Decreased by -28.00% |
| May 16, 23 | -0.26 Decreased by -119.26% | -0.27 Increased by +3.70% |
| Mar 21, 23 | -0.23 Increased by +11.54% | -0.17 Decreased by -35.29% |
| Nov 17, 22 | -0.32 Increased by +25.58% | -0.43 Increased by +25.58% |
| Aug 9, 22 | -0.22 Increased by +42.11% | -0.15 Decreased by -46.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 5.93 M Decreased by -60.65% | -26.49 M Decreased by -26.53% | Decreased by -447.00% Decreased by -221.56% |
| Jun 30, 23 | 22.35 M Increased by +48.43% | -24.61 M Decreased by -17.55% | Decreased by -110.09% Increased by +20.80% |
| Mar 31, 23 | 9.80 M Decreased by -90.48% | -15.12 M Decreased by -117.65% | Decreased by -154.38% Decreased by -285.46% |
| Dec 31, 22 | 37.65 M Increased by +139.38% | -13.26 M Increased by +21.00% | Decreased by -35.23% Increased by +67.00% |
| Sep 30, 22 | 15.06 M Increased by +133.74% | -20.93 M Increased by +23.04% | Decreased by -139.01% Increased by +67.08% |
| Jun 30, 22 | 15.06 M Increased by +190.23% | -20.93 M Increased by +12.08% | Decreased by -139.01% Increased by +69.71% |
| Mar 31, 22 | 102.91 M Increased by +1.29 K% | 85.66 M Increased by +496.62% | Increased by +83.24% Increased by +128.53% |
| Dec 31, 21 | 15.73 M Increased by +66.49% | -16.79 M Increased by +25.68% | Decreased by -106.74% Increased by +55.36% |